0000919574-20-005630.txt : 20200831
0000919574-20-005630.hdr.sgml : 20200831
20200831193300
ACCESSION NUMBER: 0000919574-20-005630
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200827
FILED AS OF DATE: 20200831
DATE AS OF CHANGE: 20200831
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ARMISTICE CAPITAL, LLC
CENTRAL INDEX KEY: 0001601086
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-25466
FILM NUMBER: 201153032
BUSINESS ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 231-4932
MAIL ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Armistice Capital Master Fund Ltd.
CENTRAL INDEX KEY: 0001633584
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-25466
FILM NUMBER: 201153033
BUSINESS ADDRESS:
STREET 1: C/O ARMISTICE CAPITAL, LLC
STREET 2: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-231-4932
MAIL ADDRESS:
STREET 1: C/O ARMISTICE CAPITAL, LLC
STREET 2: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyd Steven
CENTRAL INDEX KEY: 0001706140
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-25466
FILM NUMBER: 201153034
MAIL ADDRESS:
STREET 1: 510 MADISON AVENUE, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclo Therapeutics, Inc.
CENTRAL INDEX KEY: 0000922247
STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860]
IRS NUMBER: 593029743
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6714 NW 16TH STREET, SUITE B
CITY: GAINSVILLE
STATE: FL
ZIP: 32653
BUSINESS PHONE: 386-418-8060
MAIL ADDRESS:
STREET 1: PO BOX 1180
CITY: ALACHUA
STATE: FL
ZIP: 32616-1180
FORMER COMPANY:
FORMER CONFORMED NAME: CTD HOLDINGS INC
DATE OF NAME CHANGE: 20000913
FORMER COMPANY:
FORMER CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
DATE OF NAME CHANGE: 19941012
4
1
ownership.xml
X0306
4
2020-08-27
0
0000922247
Cyclo Therapeutics, Inc.
CTDH
0001601086
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK
NY
10022
0
0
1
0
0001633584
Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD.
20 GENESIS CLOSE, P.O. BOX 314
GRAND CAYMAN
E9
KY1-1104
CAYMAN ISLANDS
0
0
1
0
0001706140
Boyd Steven
C/O ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK
NY
10022
0
0
1
0
Common Stock, par value $.0001 per share
2020-08-27
4
S
0
55263
0.12
A
18971787
D
Common Stock, par value $.0001 per share
2020-08-27
4
S
0
0
0
A
18971787
I
See Footnote
Common Stock, par value $.0001 per share
2020-08-28
4
S
0
75000
0.11
A
18896787
D
Common Stock, par value $.0001 per share
2020-08-28
4
S
0
0
0
A
18896787
I
See Footnote
Common Stock, par value $.0001 per share
2020-08-31
4
S
0
35000
0.11
A
18861787
D
Common Stock, par value $.0001 per share
2020-08-31
4
S
0
0
0
A
18861787
I
See Footnote
Warrants
0.27
2019-05-31
2024-11-30
Common Stock
12000000
12000000
D
Warrants
0.27
2019-05-31
2024-11-30
Common Stock
12000000
12000000
I
See Footnote
Warrants
0.15
2020-08-27
2027-08-27
Common Stock
10000000
10000000
D
Warrants
0.15
2020-08-27
2027-08-27
Common Stock
10000000
10000000
I
See Footnote
The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This constitutes the weighted average purchase price. The prices ranged from $0.11 to $0.12. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Common Stock, par value $.0001 per share, following such exercise.
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member
2020-08-31
Armistice Capital Master Fund Ltd.By: /s/ Steven Boyd, Director
2020-08-31
/s/ Steven Boyd
2020-08-31